Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV
Jake A. Ruddy, Brian J. Boyarsky, Justin R. Bailey, Andrew H. Karaba, Jacqueline M. Garonzik-Wang, Dorry L. Segev, Christine M. Durand, William A. Werbel
Abstract
This study of SARS-CoV-2 mRNA vaccination in 14 persons with HIV (PWH) demonstrated uniformly high anti-SARS-CoV-2 receptor binding domain (RBD) antibody titres after two doses, despite varied titres after a single dose. The majority of vaccine reactions were mild and no adverse events occurred.
Topics & Concepts
MedicineVaccinationImmunologyAntibodyVirologyMessenger RNAAntibody responseHuman immunodeficiency virus (HIV)Adverse effectImmunopathologyLentivirusViral diseaseImmune systemHumoral immunityReceptorVirusRNASARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies